3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, B-Cell
9
Recurrence
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Non-Hodgkin
8
Burkitt Lymphoma
6
Multiple Myeloma
5
Lymphoma, Mantle-Cell
5
Lymphoma
5
Lymphoma, Follicular
4
Neoplasms
3
Neoplasm, Residual
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Pancreatic Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumors
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Platinum-Resistant Ovarian Carcinoma
1
Plasmacytoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Nasopharyngeal Carcinoma
1
Interventions
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
Cetuximab
3
Bevacizumab
3
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Leucovorin
2
Fluorouracil
2
Cisplatin
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
relacorilant
1
Long Interspersed Nucleotide Elements
1
Immunotherapy, Adoptive
1
Floxuridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Pancreatic Ductal
×
Immunotherapy, Adoptive
×
1 year
×
Clear all
NCT07153289
2025-09-03
ResCPa
University Hospital Tuebingen
Phase 1/2
Not yet recruiting
38 enrolled